|
WO2012027328A2
(en)
|
2010-08-23 |
2012-03-01 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
US10280221B2
(en)
|
2013-03-15 |
2019-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
|
AU2014323523B2
(en)
|
2013-09-20 |
2020-02-20 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
MA41463A
(fr)
*
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
PL3298021T3
(pl)
|
2015-05-18 |
2019-11-29 |
Tolero Pharmaceuticals Inc |
Proleki alvocidibu o zwiększonej biodostępności
|
|
CA2986765A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
TWI773646B
(zh)
*
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
EP3744340A3
(en)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
|
MX2018002610A
(es)
*
|
2015-09-02 |
2018-09-27 |
Immutep Sas |
Anticuerpos anti-lag-3.
|
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
JP6945456B2
(ja)
*
|
2015-11-13 |
2021-10-06 |
マクロジェニクス，インコーポレーテッド |
Ｌａｇ‐３結合分子及びその使用方法
|
|
US20190330336A1
(en)
*
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
JP6955507B2
(ja)
|
2015-12-14 |
2021-10-27 |
マクロジェニクス，インコーポレーテッド |
Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
|
|
JP7000322B2
(ja)
|
2015-12-16 |
2022-02-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗ｌａｇ３抗体および抗原結合性フラグメント
|
|
SG10201601719RA
(en)
*
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
|
UA127200C2
(uk)
|
2016-05-18 |
2023-06-07 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Молекула антитіла до pd1
|
|
US11472856B2
(en)
|
2016-06-13 |
2022-10-18 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
EP3858858A1
(en)
|
2016-06-20 |
2021-08-04 |
F-Star Delta Limited |
Binding molecules binding pd-l1 and lag-3
|
|
BR112018076525A2
(pt)
|
2016-06-20 |
2019-04-02 |
F-Star Beta Limited |
membros de ligação a lag-3
|
|
AU2017282892B2
(en)
*
|
2016-06-23 |
2023-10-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
EA039718B1
(ru)
*
|
2016-07-21 |
2022-03-03 |
Регенерон Фармасьютикалз, Инк. |
Антитела к lag3 и их применения
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
MY190805A
(en)
*
|
2016-09-08 |
2022-05-12 |
Daiichi Sankyo Co Ltd |
Antibody for treating autoimmune diseases
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
US11390676B2
(en)
*
|
2016-10-13 |
2022-07-19 |
Symphogen A/S |
Anti-LAG-3 antibodies and compositions
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
CN110650974B
(zh)
|
2017-02-10 |
2024-04-19 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
|
SG11201907561PA
(en)
*
|
2017-02-22 |
2019-09-27 |
I Mab |
Anti-lag-3 antibodies and uses thereof
|
|
EP4201953A1
(en)
|
2017-04-03 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR102294136B1
(ko)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
|
KR102737715B1
(ko)
|
2017-04-05 |
2024-12-03 |
르 라보레또레 쎄르비에르 |
Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
|
|
SG11201909395TA
(en)
*
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
MX2019012038A
(es)
|
2017-05-30 |
2019-11-18 |
Bristol Myers Squibb Co |
Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
|
|
CA3060984A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
KR102721137B1
(ko)
|
2017-05-30 |
2024-10-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11312783B2
(en)
|
2017-06-22 |
2022-04-26 |
Novartis Ag |
Antibody molecules to CD73 and uses thereof
|
|
US20190048072A1
(en)
|
2017-06-22 |
2019-02-14 |
Novartis Ag |
USE OF IL-1beta BINDING ANTIBODIES
|
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
EP3652212A4
(en)
*
|
2017-07-13 |
2021-04-14 |
Nanjing Leads Biolabs Co., Ltd. |
LAG-3 BINDING ANTIBODIES AND THEIR USES
|
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
EP3668876B1
(en)
|
2017-08-18 |
2024-01-24 |
Cothera Bioscience, Inc. |
Polymorphic form of tg02
|
|
CA3073733A1
(en)
*
|
2017-08-30 |
2019-03-07 |
Phanes Therapeutics, Inc. |
Anti-lag-3 antibodies and uses thereof
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
TW201927336A
(zh)
*
|
2017-10-05 |
2019-07-16 |
日商第一三共股份有限公司 |
細胞毒性ｔ細胞耗竭用組成物
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
WO2019108900A1
(en)
|
2017-11-30 |
2019-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
JP7489316B2
(ja)
|
2017-12-19 |
2024-05-23 |
エフ－スター セラピューティクス リミテッド |
Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
|
|
CA3085656A1
(en)
|
2017-12-22 |
2019-06-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Lag-3 antibody pharmaceutical composition and use thereof
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN111655730A
(zh)
|
2018-01-31 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
包含与lag3结合的抗原结合位点的双特异性抗体
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
CN110615840A
(zh)
*
|
2018-06-19 |
2019-12-27 |
信达生物制药(苏州)有限公司 |
全人源的抗lag-3抗体及其应用
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CU20210002A7
(es)
|
2018-07-10 |
2021-08-06 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
EP3826660A1
(en)
|
2018-07-26 |
2021-06-02 |
Bristol-Myers Squibb Company |
Lag-3 combination therapy for the treatment of cancer
|
|
EP4445958B1
(en)
|
2018-10-19 |
2025-09-24 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
JP2022511029A
(ja)
|
2018-12-04 |
2022-01-28 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2020128636A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
AU2019408408A1
(en)
|
2018-12-21 |
2021-06-03 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
JP2022514087A
(ja)
|
2018-12-21 |
2022-02-09 |
ノバルティス アーゲー |
ＩＬ－１β結合抗体の使用
|
|
AU2020221247B2
(en)
|
2019-02-12 |
2024-12-12 |
Sumitomo Pharma America, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3935581A4
(en)
|
2019-03-04 |
2022-11-30 |
Iocurrents, Inc. |
DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
AU2020248002A1
(en)
|
2019-03-26 |
2021-10-21 |
The Regents Of The University Of Michigan |
Small molecule degraders of STAT3
|
|
KR20210148131A
(ko)
|
2019-03-29 |
2021-12-07 |
닛토덴코 가부시키가이샤 |
적층체의 제조 방법, 도장물의 제조 방법, 접합 구조체의 제조 방법, 열 전사 시트, 및 적층체
|
|
US12570679B2
(en)
|
2019-03-29 |
2026-03-10 |
Regents Of The University Of Michigan |
STAT3 protein degraders
|
|
AU2020276242B2
(en)
|
2019-05-13 |
2025-01-30 |
Regeneron Pharmaceuticals, Inc. |
Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
CN115340606B
(zh)
*
|
2019-05-31 |
2023-12-19 |
瑞阳(苏州)生物科技有限公司 |
与人lag-3蛋白结合的抗体及其编码基因和应用
|
|
EP3984554A4
(en)
*
|
2019-06-11 |
2023-11-08 |
ONO Pharmaceutical Co., Ltd. |
IMMUNOSUPPRESSANT
|
|
US20220265590A1
(en)
|
2019-06-12 |
2022-08-25 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
AU2020291464A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
BR112021026334A2
(pt)
|
2019-06-27 |
2022-05-10 |
Medstar Health |
Macrófagos ativados por hdac6, composições, e usos dos mesmos
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
AU2020315401B2
(en)
|
2019-07-16 |
2025-05-22 |
The Regents Of The University Of Michigan |
Imidazopyrimidines as EED inhibitors and the use thereof
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220388978A1
(en)
|
2019-08-27 |
2022-12-08 |
Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
CN115023267A
(zh)
|
2019-09-19 |
2022-09-06 |
密歇根大学董事会 |
螺环雄激素受体蛋白质降解剂
|
|
CN114450028A
(zh)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Lag-3拮抗剂治疗的定量空间剖析
|
|
CA3158298A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
KR20220139915A
(ko)
|
2020-02-06 |
2022-10-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-10 및 그의 용도
|
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
US20230257365A1
(en)
|
2020-07-10 |
2023-08-17 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
US20230233690A1
(en)
|
2020-07-10 |
2023-07-27 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3193421A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
CA3190660A1
(en)
|
2020-08-31 |
2022-03-03 |
George C. Lee |
Cell localization signature and immunotherapy
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
CN116601140A
(zh)
|
2020-10-02 |
2023-08-15 |
羿尊生物医药股份有限公司 |
用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
|
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
EP4255929A2
(en)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
SMT202500208T1
(it)
|
2020-12-28 |
2025-07-22 |
Bristol Myers Squibb Co |
Composizioni anticorpali e metodi per il loro uso
|
|
AU2022212123A1
(en)
|
2021-01-29 |
2023-09-07 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
US20240166647A1
(en)
|
2021-03-03 |
2024-05-23 |
The Regents Of The University Of Michigan |
Cereblon Ligands
|
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
EP4337694A1
(en)
|
2021-05-12 |
2024-03-20 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
US20240417473A1
(en)
|
2021-10-29 |
2024-12-19 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
AU2022409713A1
(en)
|
2021-12-16 |
2024-06-20 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
IL314050A
(en)
|
2022-01-26 |
2024-09-01 |
Bristol Myers Squibb Co |
Combination therapy for hepatocellular carcinoma
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
JP2025508076A
(ja)
|
2022-03-08 |
2025-03-21 |
アレンティス・セラピューティクス・アクチェンゲゼルシャフト |
Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
|
|
AU2023236289A1
(en)
|
2022-03-15 |
2024-08-15 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CN119562830A
(zh)
|
2022-06-02 |
2025-03-04 |
百时美施贵宝公司 |
抗体组合物及其使用方法
|
|
US20260041745A1
(en)
|
2022-06-09 |
2026-02-12 |
Zymedi Co., Ltd. |
Novel crs fragment peptide with immunopotentiating activity, and use thereof
|
|
JP2025541725A
(ja)
|
2022-12-01 |
2025-12-23 |
メディミューン リミテッド |
抗ｐｄ－ｌ１抗体及び抗ｃｄ７３抗体を含む癌の治療のための併用療法
|
|
EP4634224A1
(en)
|
2022-12-14 |
2025-10-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
CN120731228A
(zh)
|
2022-12-21 |
2025-09-30 |
百时美施贵宝公司 |
肺癌的组合疗法
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
EP4680342A1
(en)
|
2023-03-13 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
TW202535926A
(zh)
|
2023-10-30 |
2025-09-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025151487A2
(en)
|
2024-01-08 |
2025-07-17 |
Regents Of The University Of Michigan |
Small-molecule inhibitors of adar1
|
|
WO2025184211A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
TW202606754A
(zh)
|
2024-04-23 |
2026-02-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026035866A1
(en)
|
2024-08-07 |
2026-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
|
|
US20260115307A1
(en)
|
2024-10-31 |
2026-04-30 |
Bristol-Myers Squibb Company |
Anti-fucosyl-gm1 antibody drug conjugates
|